A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

BackgroundRelatively poor penetration and retention in tumor tissue has been documented for large molecule drugs including therapeutic antibodies and recombinant immunoglobulin constant region (Fc)-fusion proteins due to their large size, positive charge, and strong target binding affinity. Therefore, when designing a large molecular drug candidate, smaller size, neutral charge, and optimal affinity should be considered.MethodsWe engineered a recombinant protein by molecular engineering the second domain of VEGFR1 and a few flanking residues fused with the Fc fragment of human IgG1, which we named HB-002.1. This recombinant protein was extensively characterized both in vitro and in vivo for its target-binding and target-blocking activities, pharmacokinetic profile, angiogenesis inhibition activity, and anti-tumor therapeutic efficacy.ResultsHB-002.1 has a molecular weight of ~80 kDa, isoelectric point of ~6.7, and an optimal target binding affinity of <1 nM. The pharmacokinetic profile was excellent with a half-life of 5 days, maximal concentration of 20.27 μg/ml, and area under the curve of 81.46 μg · days/ml. When tested in a transgenic zebrafish embryonic angiogenesis model, dramatic inhibition in angiogenesis was exhibited by a markedly reduced number of subintestinal vessels. When tested for anti-tumor efficacy, HB-002.1 was confirmed in two xenograft tumor models (A549 and Colo-205) to have a robust tumor killing activity, showing a percentage of inhibition over 90% at the dose of 20 mg/kg. Most promisingly, HB-002.1 showed a superior therapeutic efficacy compared to bevacizumab in the A549 xenograft model (tumor inhibition: 84.7% for HB-002.1 versus 67.6% for bevacizumab, P < 0.0001).ConclusionsHB-002.1 is a strong angiogenesis inhibitor that has the potential to be a novel promising drug for angiogenesis-related diseases such as tumor neoplasms and age-related macular degeneration.

[1]  N. Tebbutt,et al.  Bevacizumab in colorectal cancer: current and future directions , 2012, Expert review of anticancer therapy.

[2]  Y. Yamashita,et al.  Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. , 2009, Oncology reports.

[3]  M. Ahluwalia,et al.  Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges , 2013, OncoTargets and therapy.

[4]  Yihai Cao.  Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands , 2009, Science Signaling.

[5]  R. Eskander,et al.  Bevacizumab in the treatment of ovarian cancer , 2011, Biologics : targets & therapy.

[6]  R. Jain,et al.  Microvascular permeability of normal and neoplastic tissues. , 1986, Microvascular research.

[7]  Luzhe Sun,et al.  Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models , 2010, PloS one.

[8]  Y. Narita.  Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. , 2013, Japanese journal of clinical oncology.

[9]  Wei Zhu,et al.  Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug. , 2011, Biological & pharmaceutical bulletin.

[10]  R. Jain,et al.  Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.

[11]  R K Jain,et al.  Extravascular diffusion in normal and neoplastic tissues. , 1984, Cancer research.

[12]  L. Weiner,et al.  Antibody constructs in cancer therapy , 2007, Cancer.

[13]  L. Presta,et al.  The second immunoglobulin‐like domain of the VEGF tyrosine kinase receptor Flt‐1 determines ligand binding and may initiate a signal transduction cascade. , 1996, The EMBO journal.

[14]  Gavin Thurston,et al.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.

[15]  J. Pignon,et al.  Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Guo-qing Chen,et al.  Molecularly targeted drugs for metastatic colorectal cancer , 2013, Drug design, development and therapy.

[17]  Y. Kwan,et al.  The angiogenic effects of Angelica sinensis extract on HUVEC in vitro and zebrafish in vivo , 2008, Journal of cellular biochemistry.

[18]  K. Dimas,et al.  Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice. , 2006, In vivo.

[19]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[20]  H. Komatsu.  [Antibody therapy in cancer]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.

[21]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[22]  H. Bear,et al.  Bevacizumab and breast cancer: what does the future hold? , 2012, Future oncology.

[23]  L. Teng,et al.  Clinical Applications of VEGF‐Trap (Aflibercept) in Cancer Treatment , 2010, Journal of the Chinese Medical Association : JCMA.

[24]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[25]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[26]  B. Coomber,et al.  The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. , 2012, Neoplasia.

[27]  C. Jones,et al.  Competing roles of rising CO 2 and climate change in the contemporary European carbon balance , 2007 .

[28]  R. Samant,et al.  Recent Advances in Anti-Angiogenic Therapy of Cancer , 2011, Oncotarget.

[29]  H. Lipp,et al.  Bevacizumab, a humanized anti‐angiogenic monoclonal antibody for the treatment of colorectal cancer , 2007, Journal of clinical pharmacy and therapeutics.

[30]  E. Kremmer,et al.  Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1* , 1997, The Journal of Biological Chemistry.

[31]  C. Halin,et al.  An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. , 2002, International journal of radiation oncology, biology, physics.

[32]  G. Yancopoulos,et al.  Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  M. Saif.  Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? , 2013, Cancer management and research.

[34]  H. Hurwitz,et al.  Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. , 2012, The oncologist.

[35]  J. M. Mason,et al.  IL-4-Induced Gene-1 Is a Leukocyte l-Amino Acid Oxidase with an Unusual Acidic pH Preference and Lysosomal Localization1 , 2004, The Journal of Immunology.

[36]  S. Wiegand,et al.  Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. , 2002, Endocrinology.

[37]  E. Chu.  An update on the current and emerging targeted agents in metastatic colorectal cancer. , 2012, Clinical colorectal cancer.

[38]  Y G Meng,et al.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. , 1999, The Journal of pharmacology and experimental therapeutics.

[39]  D. Planchard.  Bevacizumab in non-small-cell lung cancer: a review , 2011, Expert review of anticancer therapy.

[40]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Debbie L Hay,et al.  Measurement of Phosphorylated Extracellular Signal–Regulated Kinase 1 and 2 in an Undergraduate Teaching Laboratory with ALPHAscreen Technology , 2009, Science Signaling.

[42]  A. Sood,et al.  Contemporary use of bevacizumab in ovarian cancer , 2013, Expert opinion on biological therapy.

[43]  L. Mao,et al.  Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer , 2009, Molecular Cancer Therapeutics.

[44]  W. Jiang,et al.  PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. , 2009, Cancer genomics & proteomics.

[45]  G. Thurston,et al.  Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors , 2010, Cancer biology & therapy.

[46]  Agustin A. Garcia,et al.  Bevacizumab and ovarian cancer , 2013, Therapeutic advances in medical oncology.

[47]  P. Ravn,et al.  Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer , 2006, The British journal of surgery.

[48]  S. Mousa,et al.  Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration , 2013, Clinical ophthalmology.

[49]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  N. Ferrara,et al.  VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.